Medicare Panel Gives Wish List For Bone Morphogenetic Protein Research
This article was originally published in The Gray Sheet
Executive Summary
Cross-industry cooperation may be needed to develop more effective bone morphogenetic proteins to promote bone growth and fusion, according to a Medicare advisory panel
You may also be interested in...
Medtronic’s Amplify Spine Product Not Approvable, FDA Says
Medtronic received a non-approvable letter from FDA for its Amplify rhBMP-2 Matrix spinal treatment, the company disclosed in a March 9 regulatory filing.
Medtronic’s Amplify Spine Product Not Approvable, FDA Says
Medtronic received a non-approvable letter from FDA for its Amplify rhBMP-2 Matrix spinal treatment, the company disclosed in a March 9 regulatory filing.
Medicare Advisors Set To Meet On BMPs; AHRQ Tech Assessment Issued
Evidence on the harms and benefits of bone morphogenetic protein orthopedic products will be scrutinized by Medicare advisors this week